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Implications of dose‐rounding intravenous chemotherapy at a community‐based hospital
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ABSTRACT

OBJECTIVES: To quantify and evaluate the total number of pharmacist interventions completed
for dose‐rounding of IV chemotherapy medications, calculate cost savings due to dose‐rounding
of IV chemotherapy medications, and identify the 5 most commonly prescribed medications
yielding the greatest cost‐savings. METHODS: Prospective, single‐center, IRB‐approved
interventional study conducted at South Miami Hospital from December 14th 2013 to March
14th 2014. All oncology patients 18 years of age and older receiving single‐dose vial intravenous
(IV) chemotherapy agents during the study period were included. On a daily basis, the primary
investigator (PI) checked the IV room in the morning and evening for chemotherapy orders. In
addition, the IV room pharmacist notified the PI regarding orders involving single‐dose vial
chemotherapy for IV use. On the other hand, a list with the names of the chemotherapy
outpatients was provided to the PI by the oncology department on the afternoon prior to the
day of the scheduled cycle. The PI reviewed orders to evaluate feasibility of dose rounding to
the nearest vial. If the order met the specified 5% dose‐rounding criteria, the PI contacted the
prescriber to make the recommendation of dose‐rounding. Once the 3 month study period was
completed, the amount of orders meeting the specified 5% limit criteria for dose rounding was
recorded; the top 5 most commonly prescribed antineoplastic agents yielding the most cost‐
savings were identified, and the overall cost‐savings associated with dose‐rounding of
chemotherapy medications during the study period was calculated. RESULTS: Eleven percent
(14 of 123) of the orders analyzed met the 5% dose‐rounding criteria. All orders (100%) were
rounded after obtaining approval from the prescriber. A total of 9634.51 dollars were saved by
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rounding the 14 orders to the vial size. The 5 most commonly prescribed medications yielding
the most cost‐savings at our institution were, in order of potential savings: Doxorubicin
(liposomal), bevacizumab, rituximab, cyclophosphamide, and pemetrexed.

INTRODUCTION

Although dosing based on body surface area (BSA) is used as the standard method for the
administration of chemotherapy medications, it is well documented that this is not a dosing
approach devoid of drawbacks1,2. This is primarily because inter‐patient variability of systemic
medication exposure involves several factors not controlled by BSA‐based dose calculations.
Dose‐rounding of antineoplastic agents is increasingly being incorporated in several institutions
within the United States and worldwide3,4. This is usually done with the ultimate goal of
improving delivery of oncological agents in busy oncology departments without compromising
the efficacy of the chemotherapeutic regimen. In most cases, the intervention entails
calculating the dose of a chemotherapeutic agent based on the patient’s BSA and then rounding
the dose within defined ranges to the nearest vial size. Substantial cost‐savings associated with
the implementation of a dose‐rounding protocol of antineoplastic agents have been previously
described in the literature5,6. In addition, unnecessary wastage of these medications is not
uncommon due to the fact that most of these medications are preservative free7. At the
present moment, there are several chemotherapeutic agents on the national drug shortage list
(Table 1). Adopting the idea of dose‐rounding can lead to an increase in the hospital inventory
of medications that are in shortage. Thus, rounding the dose of antineoplastic agents to the vial
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size is expected to result in significant cost‐savings, minimization of waste disposal8, and
increase in the institution’s inventory. In this prospective, interventional study conducted at a
not‐for profit community hospital, we hypothesized that rounding the dose of single‐dose IV
chemotherapy is a feasible process resulting in significant cost‐savings for our pharmacy
department.

METHODS

Study Design

This Prospective, single‐center, interventional study was conducted at South Miami Hospital
(SMH), a licensed 467 bed facility. The study protocol was approved and conducted in
accordance with the ethical standards of the facility’s Institutional Review Board (IRB).

Patient selection

All oncology patients 18 years of age and older receiving single‐dose vial IV chemotherapy
agents during the period of December 14th 2013 to March 14th 2014 were included. The PI
provided an in‐service to the pharmacists explaining the rationale of the study and the process
for contacting the PI when IV chemotherapy orders were received at the pharmacy (Appendix
1). A similar in‐service was provided to clinicians prescribing chemotherapy (Appendix 2), and to
nurses administering such medications (Appendix 3). All of these scripts were posted in each
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department as reminders. Patients’ information was collected by several mechanisms. The PI
checked the IV room daily in the morning and evening for chemotherapy orders. In addition,
the IV room pharmacist notified the PI regarding orders involving single‐dose vial
chemotherapy for IV use. The majority of the chemotherapy at our facility is administered to
patients who come to the hospital to receive their chemotherapy cycle as outpatient. For these
patients, the PI obtained a list of patients receiving chemotherapy from the oncology floor on
the afternoon of the day prior to patients receiving the chemotherapy.

Data analysis

The PI reviewed orders for feasibility of dose rounding to the nearest vial. If the order met the
5% criteria for dose‐rounding, the PI contacted the prescriber to make the recommendation of
dose‐rounding. A clarification of the accepted recommendation was documented in the
patient’s chart using a physician’s order form (Appendix 4). In addition, each nurse
administering the medication was verbally informed of the change in dose. The intervention,
and other data variables from the intervention were documented in a password‐protected data
collection sheet (Appendix 5). At the end of the 3‐month period, the percentage of evaluated
orders meeting the specified 5% dose‐rounding criteria was calculated. The top 5 most
commonly prescribed chemotherapeutic agents yielding the most potential cost‐savings were
identified by multiplying the doses prescribed by the price of the vial. Last, the overall cost‐
savings associated with dose‐rounding of antineoplastic agents during the study period was
calculated as follow: The cost of each product vial was obtained from our pharmacy buyer. The
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total number of vials required based on the rounded dose was subtracted from the total
number of vials required if the originally prescribed dose would have been used. The difference
was multiplied by the cost of the vial to obtain the cost saved per dose. Multiplying this by the
total number of doses rounded allowed the investigators to find the total cost‐savings for that
regimen.

RESULTS:

A Total of 123 orders met criteria to be analyzed. Of those, 14 (11%) actually met criteria for
dose rounding (Figure 1). All 14 orders (100%) were rounded after obtaining approval from the
prescriber. A total of 9,634.51 dollars were saved by rounding the 14 doses to the vial size
(Figure 2). The 5 most commonly prescribed medications yielding the most cost‐savings at our
institution were, in order of potential savings: Doxorubicin (liposomal), bevacizumab, rituximab,
cyclophosphamide, and pemetrexed.

DISCUSSION

Antineoplastic agents are the top medication class for expenditure in nonfederal hospitals, and
oncology products accounted for 32.2% of medication expenditure in the clinical setting
throughout 2012. This trend continues as there is an increase in the number of new molecular
entities approved by the Food and Drug Administration (FDA) to treat oncological disorders10. In
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this study, we have shown that the concept of dose‐rounding single‐dose IV chemotherapy is
not only feasible, but also results in significant cost savings.

Several important aspects related to this study are noteworthy mentioning. Although a
reasonable proportion of the orders prescribed at our facility met the specified 5% limit criteria,
this outcome could have been improved by using a 10% dose‐deviation. We decided to be
conservative in our study using a 5% dose‐rounding criteria and rounding down to the vial size,
as it was our first interventional study involving dose‐rounding of antineoplastic agents.
Nevertheless, the available literature supports a 10% dose deviation, which would result in
significantly more interventions and cost‐savings. For all 14 orders meeting the specified 5%
dose‐rounding criteria, the prescriber was comfortable with us rounding the dose to the vial
size. This implies that our prescribers are aware of the benefits of this intervention and are
receptive to pharmacist‐based recommendations related to cost‐containment. Some patients
had more than 1 dose rounded. This is because those patients came back for subsequent cycles
of chemotherapy. For bevacizumab, we had 1 patient receiving 3 cycles, 1 receiving 2 cycles,
and a third patient receiving a single cycle. The cost of the vial was used to determine the top 5
most commonly prescribed medications yielding the most potential cost‐savings. Although
some of the medications in this study are available in multiple vial sizes, this does not affect this
particular outcome because the cost per milligram of medication remains constant. As an
example, cyclophosphamide 500 mg vials cost $258 and therefore the 1000 mg vials cost $516
which is twice the cost.
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Several limitations were evident upon culmination of this study. First, not every
chemotherapeutic agent in our study is dosed on the basis of BSA. As an example, bevacizumab
is dosed in milligrams per kilograms. This would be inconsistent with the rationale behind using
BSA to dose chemotherapy specified in this study. However, several studies have shown that
rounding the dose of this agent to the vial size results in cost‐savings without affecting clinical
outcomes. Our study was conducted over a relatively short amount of time. This may explain
the small sample size collected and the relatively small, although substantial, amount of money
saved. Implementation of an automatic dose‐rounding protocol using the presented data may
confirm the much bigger benefit of dose‐rounding single‐dose IV chemotherapy at our
institution.

CONCLUSION

The results of this prospective, interventional study, were consistent with our hypothesis that
dose‐rounding antineoplastic agents would result in significant cost‐savings for our pharmacy
department. This is consistent with others studies which have targeted similar endpoints6,7. It is
evident from this study that dose‐rounding chemotherapy is feasible and that oncologists are
receptive to the idea of dose‐rounding. We identified the 5 most commonly prescribed
chemotherapeutic agents at our institution, and we intend to obtain approval for an automatic
dose‐rounding protocol for these agents based on the results of this study. Nevertheless, the
data presented in this study would support the implementation of a dose rounding protocol
involving any single‐dose IV antineoplastic agent.
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Figure 1. Percentage of patients meeting the specified 5% dose‐rounding criteria

159 orders reviewed for 51 patients

123 (77%)

36 (23%)

Included

Excluded

14 (11%)
Met 5% criteria*

109 (89%)
Did NOT meet 5%
criteria

Reasons for exclusion
‐ 33 Multi‐dose vials
‐ 3 Non‐cancer indication

*All interventions were made by phone and were accepted by the prescriber
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Figure 2. Total amount of US dollars saved by dose‐rounding 14 orders to the vial size

Medication

Doses
Rounded

Amount of
patients
rounded

Amount Saved
(US Dollars)

Avastin (Bevacizumab)

6

3*

3,739.02

Alimta (Pemetrexed)

1

1

2,831.76

Rituxan (Rituximab)

2

1

1,317.30

Doxil
(Liposomal Doxorubicin)

1

1

1,131.00

Cytoxan (Cyclophosphamide) 2

1

516.98

14

Taxotere
(Docetaxel)

1

1

94.21

Adriamycin
(Conventional Doxorubicin)

1

1

4.24
9,634.51

*

Patient 1 received 3 doses, patient 2 received 2 doses, and patient 3 received 1 dose

Figure 3. Top 5 most commonly prescribed medications yielding the most potential cost‐savings

Medication

Doses
prescribed

Vial price
(US dollars)

Potential Savings
(US dollars)

Doxorubicin (Liposomal)

17

1,132

19,244

Bevacizumab

11

623

6,853

Rituximab

7

659

4,613

Cyclophosphamide

16

258

4,128

Pemetrexed

1

2,832

2,832

Docetaxel

19

94

1,786

Doxorubicin (Conventional)

11

4

44
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Table 1 – List of chemotherapy medications currently in shortage status*

IV Drug Name
Revision Date
Cytarabine
August 05, 2003
Dacarbazine
October 07, 2013
Daunorubicin HCL
September 30, 2013
Doxorubicin
October 09, 2013
Doxorubicin Liposomal
September 27, 2013
Fludarabine
August 28, 2013
Methotrexate
September 12, 2013
Mitomycin
August 29, 2013
Paclitaxel
October 10, 2013
Vinblastine
September 04, 2013
* A comprehensive list of current drugs in shortage is found at: http://ashp.org/menu/DrugShortages

